骨髓间充质干细胞（MSCs）治疗缺血性心脏病是目前干细胞研究领域的热点，然而单独MSCs 治疗存在干细胞存活率低及长期疗效并不显著的问题，因此，对MSCs进行修饰和处理是目前研究的难点问题。七氟烷是一种广泛用于临床的吸入麻醉药，诸多离体及在体研究显示七氟烷治疗缺血性心脏病疗效显著。有研究表明七氟烷具有促进MSCs血管新生的作用，但其分子机制还不明确，而经典瞬时感受器电位通道6（TRPC6）对内皮细胞增殖及血管新生起重要作用。因此，本项目拟通过体内体外实验评价七氟烷促进MSCs 血管新生的作用及抗心肌缺血的保护作用，并以TRPC6作为切入点阐明七氟烷促进MSCs 血管新生的分子机制。本项目的开展不仅有助于揭示七氟烷与MSCs联合应用治疗心肌缺血的作用机制，而且能为MSCs成功应用于临床提供有益的实验探索，积极推动转化医学的发展。

Treatment of ischemic heart disease by marrow-derived mesenchymal stem cells (MSCs) is the hot spots on current stem cell research, however, only MSCs treatment exists some problems such as low cell survival rates and no significance in long-term efficacy. Therefore, modification on MSCs is the difficult problem in current researches. Sevoflurane, a inhaled anesthetic, is widely used in clinical anesthesia. Many in vitro and in vivo studies have shown that sevoflurane exerted an effective treatment on ischemic heart disease. Some studies showed sevoflurane promoted angiogenesis of MSCs, but its molecular mechanism is unknown. And Transient receptor potential canonical channel 6 (TRPC6) plays a role in proliferation of endothelial cells and angiogenesis. Therefore, this project aims to evaluate angiogenesis of MSCs promoted by sevoflurane and protective effect against myocardial ischemia in vitro and in vivo experiments. Furthermore, the TRPC6 is studied to clarify the molecular mechanisms involved in angiogenesis of MSCs promoted by sevoflurane. The launching of this project will help to clarify the mechanism the efficacy of MSCs by sevoflurane pretreatment on ischemic heart disease, it also provide the experimental basis for MSCs clinical application and promote the development of translational medicine.